A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506419-16-00

Acronym

C25003

Enrollment

448

Registered

2024-02-06

Start date

2013-01-08

Completion date

Unknown

Last updated

2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Classical Hodgkin Lymphoma

Brief summary

Modified PFS per IRF assessment using the Revised Response Criteria for Malignant Lymphoma

Detailed description

Overall survival

Interventions

DRUGDetimedac 200 mg

DRUGPulver zur Herstellung einer Injektions-/Infusionslösung

DRUGVinblastine Sulfate 1 mg/ml solution for injection

DRUGDoxorubicinhydrochlorid Teva® 2 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUGVinblastinsulfat Teva® 1 mg/ml Injektionslösung

DRUGDacarbazine medac 200 mg

DRUGpowder for solution for injection/infusion

DRUGDoxorubicin hydrochloride 2 mg/ml solution for infusion

DRUGBleomycin 15000 IU Powder for solution for injection/infusion

DRUGBleomedac®

DRUGADCETRIS 50 mg powder for concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Modified PFS per IRF assessment using the Revised Response Criteria for Malignant Lymphoma	—

Secondary

Measure	Time frame
Overall survival	—

Countries

Belgium, Czechia, Denmark, France, Hungary, Italy, Norway, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026